PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 139 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3 | -40.0% | 163 | 0.0% | 0.00% | – |
| Q2 2023 | $5 | +25.0% | 163 | 0.0% | 0.00% | – |
| Q1 2023 | $4 | +100.0% | 163 | 0.0% | 0.00% | – |
| Q4 2022 | $2 | -99.8% | 163 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 163 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | -75.0% | 163 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -33.3% | 163 | 0.0% | 0.00% | – |
| Q4 2021 | $6,000 | +100.0% | 163 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | -25.0% | 163 | +101.2% | 0.00% | – |
| Q2 2021 | $4,000 | +100.0% | 81 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 81 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | -50.0% | 81 | -58.7% | 0.00% | – |
| Q3 2020 | $4,000 | +300.0% | 196 | +27.3% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 154 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 154 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | – | 154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |